Table 1 Characteristics of patients at ICU admission

Demographics

 Age

60 [37–67.5]

 Male gender

42 (59%)

Comorbidities

 Hypertension

10 (14%)

 Diabetes

3 (4%)

 Chronic kidney disease

2 (3%)

 Body mass index (kg/m²)

24 [22–26]

ECOG Performance status

 Median PS

1 [1–2]

 PS 0

11 (15.5%)

 PS 1

32 (45%)

 PS 2

22 (31%)

 PS 3

6 (8.5%)

Hematological malignancy

 Diffuse large B cell lymphoma

53 (75%)

 Lymphoblastic leukemia

17 (24%)

 Multiple myeloma

1 (1%)

 Time between hematological diagnosis and ICU admission (months)

12 [10–16]

Previous hematological treatments

 Number of treatment lines prior to CAR-T cells

3 [3–4]

 Autologous stem cell transplantation

10

 Bone marrow transplantation

5

 Blinatumomab

11

CAR-T cell therapy

 Autologous CAR-T cells

69

 Axicabtagene ciloleucel

33 (46%)

 Tisagenlecleucel

31 (44%)

 Brexucabtagene autoleucel

4 (5.5%)

 bb2121

1 (1.5%)

 Allogeneic CAR-T cells (UCART19)

2 (3%)

 Time between CAR-T cell infusion and ICU admission (days)

6 [4–7]

Clinical and biological features at ICU admission

 Mean arterial blood pressure (mmHg)

68 [60–81]

 Temperature (°C)

39.5 [38.5–40]

 Neutropenia

47 (66%)

 SOFA score

4 [2–6]